Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 125273
Published online Nov 15, 2026. doi: 10.4251/wjgo.125273
Published online Nov 15, 2026. doi: 10.4251/wjgo.125273
Table 4 Biologic strategies for inflammatory bowel disease
| Biologic effect | Treatment | Dose scheme | Mechanism | Response | Ref. |
| TNF-α inhibitor | Infliximab | Induction: Intravenously 5 mg/kg, 2 weeks and 6 weeks | Monoclonal antibody against TNF-α | Clinical remission, reduced fistulous disease in UC | [91,180,181] |
| Maintenance: Every 8 weeks thereafter | |||||
| Adalimumab | Induction: 160 mg followed by 80 mg after two weeks | Fully humanized IgG1 monoclonal antibody against TNF-α | Induction and maintenance of remission in CD | [91,182,183] | |
| Maintenance: 40 mg every two weeks | Some patients do not respond | ||||
| Ustekinumab | Induction: 130 mg fixed dose or 6 mg/kg for 8-12 weeks | IgG1 monoclonal antibody that binds to p40 subunit of pro-inflammatory IL 12 and 23 | Clinical remission in UC | [90,91,180,184] | |
| Maintenance: 90 mg every 8-12 weeks | |||||
| Risankizumab | Induction: 600 mg for12 weeks, or 1200 mg at 0 weeks, 4 weeks, and 8 weeks | Antibody binds to p19 subunit of IL-23 | Improved clinical remission rate with short-term efficacy and safety in moderate-to-severe UC | [91,185] | |
| Maintenance: 180 mg or 360 mg every 8 weeks | |||||
| Anti-adhesion molecule inhibitors | Vedolizumab | Induction: 300 mg at initial, 2 weeks and 6 weeks | Monoclonal IgG1 antibody against α4-β7 integrin, and disruption of lymphocyte trafficking | Clinical and safety outcomes at 6-10 weeks in moderately to severe CD | [91,186] |
| Maintenance: Same dose every 8 weeks | |||||
| JAK inhibitors | Upadacitinib | Induction: 45 mg/day for 12 weeks | Immunosuppression by targeting JAK1 | Clinical remission and endoscopic response in CD | [91,187,188] |
| Maintenance: 15-30 mg/day for 52 weeks | Improvement of fecal calprotectin and C-reactive protein levels | ||||
| Tofacitinib | Induction: 10 mg twice a day for 8 weeks | Inhibition of JAK1 and JAK3, JAK2 and TYK2, blocking signaling for IL-2, IL-4, IL-6, IL-7, IL-9, IL-15, IL-21, and IFN-γ cytokines | Clinical response improvement and reduce of inflammatory markers in UC | [90,91,189-191] | |
| Maintenance: 5-10 mg twice a day for 26 weeks |
- Citation: Delgado-Gonzalez P, Quiroz-Reyes AG, Simental-Mendía MA, Loaiza-Gutiérrez VL, Garza-Treviño EN. Inflammation-driven carcinogenesis in ulcerative colitis: Molecular and immunological pathways. World J Gastrointest Oncol 2026; 18(11): 125273
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/125273.htm
- DOI: https://dx.doi.org/10.4251/wjgo.125273